December 7, 2022 – Kainomyx, Top 5 out of 139 Global Startup Companies Tackling Malaria - US-based startup Kainomyx offers small molecule therapeutics for neglected tropical diseases, with a focus on malaria. The startup’s proprietary platform combines parasite biology with biochemical and biophysical approaches to target pivot components of parasites. It targets cytoskeletal proteins of parasites to advance drug development and offers tests to identify asymptomatic carriers. Kainomyx’s solutions aid in the treatment of parasitic tropical diseases and facilitate early case detection to devise appropriate control measures in endemic situations.
October 4, 2021 – Kainomyx secured $6M in a new financing round to promote its malaria therapeutics program as well as to advance programs in malaria diagnosis and therapeutics in other parasitic diseases.
September 22, 2021 - Kainomyx was awarded a $1.97M grant from the Bill and Melinda Gates Foundation.
September 22, 2021 - “Kainomyx was highlighted in a recent article on Forbes “Impact 50: Investors Seeking Profit—And Pushing For Change”.
September 1, 2021 – Kainomyx moved to new space at 3160 Porter Drive, Palo Alto, CA 94304, in Stanford University’s Research Park. The 92,000-square-foot building was purchased from Stanford by Alexandria Real Estate Equities, Inc in 2019 and has been converted to modernized research space with a concept that fosters early- and growth-stage life science companies.
May 27, 2020 – Kainomyx is incubating in space at Cytokinetics. James Spudich, co-founder and CEO of Kainomyx, co-founded Cytokinetics, the first company devoted to developing small molecule therapeutics targeting the molecular motor-based machinery of cells, in 1998.
April 15, 2020 – Three members have been added to the Board of Directors of Kainomyx. William J. Rutter, PhD, co-Founder of the early biotech company Chiron and multiple additional companies, is Chairman of the Board of Kainomyx. Rutter is Founder, Chairman and CEO of Synergenics, LLC, which controls a consortium of companies with different but complementary approaches to diagnosis, prevention and treatment on a worldwide basis. He joins James Spudich, PhD, CEO of Kainomyx and co-founder of Cytokinetics and MyoKardia. Dirk Thye, MD, serial entrepreneur who has led multiple small and medium sized companies in successful product development, and currently Executive Chairman at Geom Therapeutics, is an independent third member of the Board. The fourth Board member is Amit L. Mehta, PhD, a Life Science Research Foundation Fellow at Bell Labs and Stanford University in his early career, became an Associate Partner at McKinsey and Company, followed by Managing Director positions at Morgan Stanley and Goldman Sachs, and is currently Managing Director at J.P. Morgan.
February 1, 2020 – Kainomyx hired James A. Spudich to assume the position of CEO in the company.
September 4, 2019 – Kainomyx was founded by five Stanford scientists who are experts in the biology, biochemistry and biophysics of the cytoskeleton of cells – James Spudich, PhD, Annamma Spudich, PhD, Darshan Trivedi, PhD, Suman Nag, PhD, and Kathleen Ruppel, MD,PhD.